Tirzepatide (30 mg Vial) Dosage Protocol
Research guide for gradual escalation dosing and reconstitution procedures for Tirzepatide, a dual GLP-1/GIP receptor agonist investigated for metabolic regulation.
Quickstart Highlights
Tirzepatide operates through simultaneous stimulation of both GLP‑1 and GIP receptors, featuring an extended half-life of approximately 5 days that permits convenient weekly subcutaneous injections. This dual receptor mechanism promotes glucose-dependent insulin release while diminishing glucagon output and creating appetite reduction through delayed gastric processing.
- Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration
- Weekly dosing schedule: 2.5 mg → 5 mg → 7.5 mg → 10 mg over 16 weeks
- Easy measuring: At 10.0 mg/mL, 1 unit = 100 mcg on a U-100 insulin syringe
- Storage: Lyophilized: −20 °C (−4 °F), dry/dark conditions; after reconstitution: 2–8 °C (35.6–46.4 °F), protected from light, use within 28 days
Dosing & Reconstitution Guide
Standard Gradual Approach for weekly subcutaneous administration
Weekly Subcutaneous Protocol (3 mL = 10.0 mg/mL)
| Phase | Weekly Dose | Syringe Volume | Duration |
|---|---|---|---|
| Initial | 2.5 mg | 0.25 mL (25 units) | Weeks 1–4 |
| Phase 2 | 5 mg | 0.50 mL (50 units) | Weeks 5–8 |
| Phase 3 | 7.5 mg | 0.75 mL (75 units) | Weeks 9–12 |
| Phase 4 | 10 mg | 1.0 mL (100 units) | Weeks 13–16 |
Administration: Subcutaneous injection once weekly on the same day. Dosing increases occur every 4 weeks as tolerated; higher doses up to 15 mg/week may follow.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with sterile syringe
- Inject slowly down vial wall; avoid foaming
- Gently swirl/roll until dissolved (do not shake)
- Label with reconstitution date and refrigerate at 2–8 °C
- Use within 28 days of reconstitution
Result: 10.0 mg/mL concentration; 1 unit (U-100 syringe) = 100 mcg
Storage Guidelines
- Lyophilized: −20 °C (−4 °F)
- Reconstituted: 2–8 °C (35.6–46.4 °F); do not freeze
- Shelf life: 28 days after reconstitution
Key Administration Notes
- Rotate injection sites to prevent lipohypertrophy
- Gastrointestinal effects common initially; titration minimizes them
- Document weekly dose, date, and injection site
- Use sterile syringes; dispose in sharps container
- Allow vials to reach room temperature before opening
⚠️ Research & Educational Purposes Only
This information is provided for research and educational purposes only. Peptides discussed are intended for laboratory research use only and are not approved for human consumption. Always consult qualified healthcare professionals for medical advice. Individual results may vary. This is not medical advice.